The latest update is out from NLS Pharmaceutics ( (NLSP) ).
On May 5, 2025, NLS Pharmaceutics Ltd. announced a third amendment to its merger agreement with Kadimastem Ltd. and NLS Pharmaceutics (Israel) Ltd., extending the termination date to June 30, 2025. This extension reflects the parties’ commitment to completing the merger diligently, ensuring all regulatory requirements are met, which could impact the company’s strategic positioning and stakeholder interests.
More about NLS Pharmaceutics
NLS Pharmaceutics Ltd. is a Swiss-based company operating in the pharmaceutical industry, focusing on developing innovative therapies for rare and complex central nervous system disorders.
YTD Price Performance: -27.52%
Average Trading Volume: 942,200
Technical Sentiment Signal: Buy
Current Market Cap: $3.91M
Learn more about NLSP stock on TipRanks’ Stock Analysis page.